Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UL17

UPID:
TBX21_HUMAN

ALTERNATIVE NAMES:
T-cell-specific T-box transcription factor T-bet; Transcription factor TBLYM

ALTERNATIVE UPACC:
Q9UL17

BACKGROUND:
The T-box transcription factor TBX21, known alternatively as T-bet, is a lineage-defining transcription factor critical for Th1 cell differentiation. It activates transcription of genes essential for Th1 function and represses genes for Th2 and Th17 lineages, playing a key role in immune response modulation. TBX21's ability to regulate antiviral B-cell responses and promote antiviral antibody isotype switching further emphasizes its importance in controlling immune responses.

THERAPEUTIC SIGNIFICANCE:
Given TBX21's involvement in conditions such as Asthma, with nasal polyps and aspirin intolerance, and Immunodeficiency 88, its study offers promising avenues for the development of targeted therapies. Exploring TBX21's mechanisms could lead to breakthroughs in treating these immune-mediated diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.